Recent USP Updates May, 2013

Similar documents
Microbiological Consideration for Non-Sterile Pharmaceutical

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC

This compilation of the complex


Environmental Monitoring of Aseptic Processing Areas - 1

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities

Overview of a sterility assurance program for PET drugs

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD

Overview and Introduction Annex 1 Revision

SFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

TECHNICAL LEAFLET. MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S)

Packaging Operations Technical Subcommittee

Metrics in Microbiology Monitoring Practices

SFHPHARM19 - SQA Unit Code FA32 04 Prepare aseptic products and carry out in-process checking

Contact details: Anna Silvani

MINIMUM REQUIREMENTS FOR A VENDOR

Infection and Intravenous Drug Delivery: A Long and Tumultuous Relationship

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>

Bioburden Contamination Control: A Holistic Overview

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

GMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document.

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

FDA s Guidance for Industry

Contents. Contents (13) 1 Production (23)

Environmental Monitoring of Aseptic Processing Areas - 2

Calibration in the Laboratory

Comments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP

USP <1223> Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA

ANNEX 1: COMMENT SUBMISSION DOCUMENT

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations

USP <1116> and Contamination

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

LUNCH AND LEARN. September 11, CE Activity Information & Accreditation

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

PhEn-602 Notes # 4 J. Manfredi

Position: Sr. Director of Education and Data - NHIA, VP of Research - NHIF

Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló

Overview of Inspection Issues with Legacy Products

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

A risk based approach to managing environmental excursions

Julie Roberts. Audit hot Topics and Regulatory Requirements

EU and FDA GMP Regulations: Overview and Comparison

Best Practice in Environmental Monitoring

Baxa Corporation. Technical Paper. Environmental Controls for Sterile Compounding

Compounding Pharmacies and Water

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

History and Update of Chapters 797 and 800

Table of Contents. Legal Notices... 61

Allergy Laboratories, Inc. 10/4/13

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Guidance for Industry

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Microbiological Cleaning Method Validation

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry

USP <797> Compliance Common Challenges and Potential Solutions

The Parenteral Drug Association

GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES

Pharmacy Compounding: Infection Prevention

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

HardyVal TM CSP RANDOM TEST KIT

Webinar Expert Module 3: GMP Inspections Dupont

Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.

Journal of Atoms and Molecules

Overview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Compounding Aseptic Isolators (CAI) James T Wagner

Ranbaxy Laboratories, Ltd., Dewas, India 16-Sep-08

CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS

PDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Pre-Sterilization Bioburden Failures and Causes

4.5 Compounding Compounding in Licensed Pharmacies.

Latest USP Initiatives: Monographs, General Chapters, and Compounding

Complaints Investigations Root Cause Analysis

ICH Q8/Q8(R)

STANDARDS FOR COMPOUNDING PHARMACIES

Q8 Pharmaceutical Development

Advances in Sterility Assurance: Single Use Devices and Rapid Microbiological Tests

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

Cleaning validation of cleanrooms and preparation equipments

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT

White Paper. Risk Management in Environmental Monitoring: Should you be spotting it sooner?

EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT

CGMP for Phase 1 INDs

Data Integrity Prioritization and Gap Analysis to Prove Data Integrity

Annex 4. Guidance on good manufacturing practices: inspection report. Background

Transcription:

Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products <1115> The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based approach to bioburden control in non-sterile drug products Content of <1115> Introduction Guidance Documents Microbial Control Considerations in Product Development Microbial Control Considerations in Routine Manufacturing Water Systems and Usage Role of Active Pharmaceutical Ingredients, In-process Materials and Excipients Equipment Design and Use Considerations Personnel The Manufacturing Environment Microbial Assessment of Nonsterile Product Manufacturing Environments Microbial Sampling Microbial Control of Drug Substance Manufacturing Overall Management of a Microbiological Control Program 1

<1115> approach A scientific approach to the management of the microbial bioburden in non-sterile products requires consideration of patient risk and control objectives. Ariskbased risk-based approach to control potential contamination in non sterile product manufacturing. It is important to understand that the manufacture and management of microbiological content of non-sterile products is distinctly different from that required for sterile products. Microbiological Influences What to learn from <1115> A microbiological contamination control program should be developed with identifying and controlling product risk based upon a formal assessment of risk modalities. The risk analysis activity should result in the establishment of critical control points and should facilitate proper equipment selection, process and facility design requirements. To be published in July August 2013 issue of Pharmacopeial Forum. 2

<1116> Microbiological Control and Monitoring of Aseptic Processing USP 35 NF 30 (2012) ISO-14644 standards are referenced for clean rooms New paradigm for monitoring control of clean rooms based on trending contamination rates Discussion about uncertainty of microbial recovery in ultra clean environments Overview of <1116> Contamination rates suggested instead of alert and action levels for manned and unmanned environments. Suggestion for investigation in the event of a significant excursion, which is defined as >15CFU for surface, personnel, or active air sampling. Discussion on analytical measurement and result interpretation. Intended to be applied only for environments in which aseptic processing is performed / supported; Drops all reference to EU Grades; all clean room classification is based upon ISO 14644. Contamination Rate Table 3 3

Classifications and Applicability in <1116> A comment made by several stakeholders on the final revision of <1116> was that they could not meet the incidence rate expectations for some ISO 7 and ISO 8 rooms. This question raises a general issue regarding attempts to apply similar or identical requirements to rooms of the same classification but differing contamination control intention. Not all rooms of the same ISO classification can be expected to perform at the same level of microbiological contamination control. Aseptic Processing and <1116> We developed <1116> with the intention that it applied only to classified clean space in which full aseptic gowning was required. ISO 7 or 8 environments that do not require full aseptic gowning will in most cases not meet the contamination rates recommended in <1116>. <1116> will not apply to many preparation rooms, sterilizer rooms, corridors, or even changing rooms prior to the donning of the full aseptic gown. Users should develop their own rate criteria for their controlled and classified environments that do not require complete aseptic gowning. Summary of <1116> We believe that the contamination rates in <1116> are routinely attainable in aseptic environments where typical lfull gowning is required. Microbiological classification of environments is not a value added activity. It is analytically wrong to treat minor differences such as 1CFU compared to 3 or 4CFU to be significant from a process control perspective. EM should be treated as a general hygienic survey rather than a measure of sterility assurance. 4

Why the designation of 15CFU as a significant excursion? Assessment of environmental contamination is not a precise science, it is not at all clear that a finding of 8CFU is clearly more significant that one of 2CFU or 3CFU. 15CFU is a result that is more likely to be the result of a significant ifi excursion rather than the result of a sampling artifact. If a finding of 15CFU or more turns out to be an isolated finding and does not correlate with short term increase in contamination rate it may not warrant any corrective action. Two General Information chapters Aseptic Process Bioburden Control of Non-sterile A pragmatic approach to educate 5